# US 8,148,327 B2 · Aldosterone induced elastin production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,148,327 B2
- Document ID: US8148327B2
- Status: Granted
- Kind: B2
- Application number: 12/157,141
- Filed: 2008-06-06
- Published: 2009-02-12
- Granted: 2012-04-03
- Earliest claimed: 2007-06-06
- Assignees: Human Matrix Sciences, LLC; The Hospital for Sick Children
- Inventors: Thomas Mitts; Aleksander Hinek
- Web page: https://patentgrep.com/patent/US8148327B2

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- C07J 21/00: Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07K 16/26: against hormones {; against hormone releasing or inhibiting factors}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.

## Claims

### Claim 1

A method for increasing the net deposition of elastin in skin comprising:
administering an effective amount of a collagen inhibitor and an effective amount of aldosterone to the skin of a subject affected by a condition selected from the group consisting of keloids, aging, stretch marks, overly stretched skin, sun damaged skin, scar tissue, supravalvular aortic stenosis (SVAS), Williams-Beuren syndrome (WBS), Cutis Laxa, Marfan disease, GM-1-gangliosidosis, Morquio B, Hurler disease, Costello syndrome, Ehlers Danlos syndrome, pseudoxanthoma elasticum (PXE), and combinations thereof, wherein the net deposition of elastin is increased in the skin.

### Claim 2 (depends on 1)

The method of claim 1, wherein aldosterone affects the skin in a mineralocorticoid receptor independent manner.

### Claim 3 (depends on 1)

The method of claim 1, wherein aldosterone and the collagen inhibitor are administered simultaneously.

### Claim 4 (depends on 1)

The method of claim 1, wherein the collagen inhibitor is administered prior to aldosterone.

### Claim 5 (depends on 1)

The method of claim 1, wherein the collagen inhibitor is selected from the group consisting of spironolactone, eplerenone, canrenone and a mineralocorticoid neutralizing antibody.